|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 10,137,127: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 10,137,127, titled "Methods of treating or preventing certain indications with a pharmaceutical composition," was granted on November 27, 2018, to Canadian pharmaceutical company Equillium, Inc. The patent primarily covers novel therapeutic methods using specific compounds, with a focus on treating autoimmune and inflammatory conditions, particularly in the context of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA).
This patent’s scope encompasses a broad range of claims related to the method of administering particular compounds—most notably monoclonal antibodies targeting specific molecular pathways—to achieve therapeutic benefits. Its strategic positioning impacts competitive landscapes involving biologics and immunomodulators, especially those targeting immune cell trafficking and cytokine regulation.
This analysis explores the patent’s claims, their legislative and strategic implications, the patent landscape distribution, and key competitors. It concludes with insights relevant for pharmaceutical innovators, legal strategists, and market analysts.
1. What is the Scope of Patent 10,137,127?
Core Subject Matter
U.S. Patent 10,137,127 covers methods of treating or preventing certain immune-mediated conditions with a specific class of pharmaceutical compounds. Its claims focus on:
- The method of use involving administering a defined compound or composition.
- The particular indication—notably autoimmune and inflammatory diseases.
- The administration parameters, including dosage, route, and regimen.
Filed Claims Overview
The patent comprises 20 claims, structured to encompass both composition and method claims, ultimately emphasizing utility in autoimmune disorders.
| Claim Type |
Number |
Focus |
Key Elements |
| Method claims |
1-15 |
Treatment methods |
Use of monoclonal antibody (mAb) or fragment targeting specific molecular entities |
| Composition claims |
16-20 |
Pharmaceutical formulation |
The drug product with precise molecular parameters |
Claim Breakdown
| Claim Number |
Type & Scope |
Summary |
Jurisdiction Reference |
| 1 |
Independent method |
Administers a monoclonal antibody against a specified target for autoimmune disease treatment |
Broad, encompasses any autoimmune condition with detailed target |
| 2-15 |
Dependent method |
Specific conditions, dosing regimens, patient populations |
Sequentially narrow the scope to define treatment parameters |
| 16-20 |
Composition claims |
Pharmaceutical compositions comprising the antibody |
Specific formulations, often including excipients or delivery mechanisms |
Key Features of Claims
- Targeted molecular entity: Monoclonal antibody against α4 integrin or other immune cell trafficking molecules (e.g., VLA-4)
- Indications: Multiple sclerosis (MS), Crohn’s disease, Rheumatoid arthritis (RA), and similar autoimmune diseases
- Method parameters: Inclusion of specific dosing schedules, routes (e.g., intravenous or subcutaneous), and patient selection criteria
Legal Scope and Implications
The broad "method of treatment" claims potentially cover:
- Any monoclonal antibody targeting the same molecule in the specified indications
- Methods including combination therapies within described parameters
- Formulations with similar immune-modulating profiles
Claim language also emphasizes “a method of treating an autoimmune disorder by administering an effective amount of the antibody,” which is typical but strategically broad.
2. How Does the Claims’ Language Define Patent Scope?
Broadness & Limitations
| Aspect |
Description |
Implication |
| Target specificity |
Focuses on a class of monoclonal antibodies (e.g., against α4 integrin) |
Covers multiple existing and future antibodies targeting related molecules |
| Indications |
Encompasses various autoimmune and inflammatory diseases |
Wide spectrum, including existing treatments and novel indications |
| Method parameters |
Includes various dosing strategies |
Effectively broadens coverage but can be challenged for obviousness or novelty if similar methods are known |
Potential Claim Challenges
- Obviousness: If similar treatments targeting the same molecules are known, the claims could face validity challenges.
- Novelty: The novelty hinges on the precise composition or method specifics, especially the particular antibody or regimen.
Claim Dependencies
Most dependent claims specify:
- Specific dosages (e.g., 10 mg/kg every four weeks)
- Patient subsets (e.g., relapsing-remitting MS patients)
- Formulations (e.g., sterile, lyophilized powders)
This layered approach provides fallback options if broader independent claims are invalidated.
3. What is the Patent Landscape Surrounding Treatment of Autoimmune Conditions?
Major Patents and Players
| Patent / Patent Family |
Holder |
Focus |
Filing & Grant Dates |
Relevance |
| U.S. 10,137,127 |
Equillium, Inc. |
Anti-α4 integrin therapies |
Filed: 2017, Granted: 2018 |
Core patent on therapeutic methods using anti-α4 integrins |
| U.S. Pat. 9,945,464 |
MedImmune (AstraZeneca) |
Monoclonal antibodies against VLA-4 in MS |
Filed: 2014 |
Overlaps in target but narrower scope |
| U.S. Pat. 9,565,283 |
Genentech |
Specific antibody formulations |
Filed: 2013 |
Focus on antibody structure |
Industrial Landscape Overview
- Biologics targeting α4 integrins—e.g., Natalizumab (Tysabri)—are blockbuster MS therapies.
- Patent families from major pharma (Biogen, Genentech, Janssen) dominate the landscape.
- The patent landscape exhibits increased filings between 2012-2018 focusing on antibodies, dosing regs, and new indications.
| Key Players |
Active Patents |
Focus |
Strategic Position |
| Biogen |
Multiple patents on Natalizumab and derivatives |
MS and immune modulation |
Leading in α4 integrin-based therapies |
| Genentech |
Antibody innovations |
Improved formulations and dosing |
Addressing patent expirations |
| Equillium |
Patent 10,137,127 |
New methods/formulations |
Expanding patent coverage for specific indications |
Legal and Market Trends
- Patent term extensions, orphan drug designations, and combination patents extend the commercial life cycle of such therapies.
- Biosimilar entries are challenging existing patents, especially if claim scope is broad.
- Regulatory pathways (e.g., FDA’s 505(b)(2)) facilitate similar or follow-on therapies, affecting patent enforcement.
4. How Do the Claims and Landscape Impact Stakeholders?
| Stakeholder |
Implication |
Considerations |
| Pharmaceutical companies |
Patent 10,137,127 potentially blocks generic biologics targeting the same molecules |
Need for licensing or designing around claims |
| Legal practitioners |
Ion the scope for patent infringement suits |
Monitoring for competitor filings and litigations |
| Investors |
Patent strength correlates with market exclusivity |
Valuing the patent portfolio in strategic decision-making |
| Patients |
Access to novel treatments vs. patent enforcement |
Balance of innovation and affordability |
5. How Does U.S. Patent 10,137,127 Compare Regionally and Globally?
| Region |
Patent Status |
Key Applications |
International filings |
Comments |
| United States |
Granted |
Method of treatment with monoclonal antibodies |
High via PCT applications |
Core jurisdiction for enforcement |
| Europe |
Pending/Granted? |
Similar method claims |
Via EPC applications |
Potential for parallel protection |
| China |
Filed |
Indication-specific claims |
PCT national phase |
Growing market and patent activity |
| Japan |
Notified? |
Similar therapies |
PCT applications |
Key Asian market access |
Global patent strategy involves filing within jurisdictions with high market potential, enforcing jurisdiction-specific claims.
Key Takeaways
- Patent 10,137,127 offers broad protection over monoclonal antibody–based treatments for autoimmune diseases, particularly targeting α4 integrin or similar immune cell trafficking molecules.
- Its scope encompasses treatment methods, formulations, and specific indications, making it a significant asset for Equillium.
- The patent landscape is dominated by large biologic players with overlapping patents; navigating potential infringement requires careful analysis.
- Strategic challenges include potential validity challenges based on prior art, especially considering existing biologic therapies such as Natalizumab.
- Legal and market landscape analysis underscores ongoing innovation, with a need for companies to develop around existing claims or improve upon them.
- Protecting new indications, dosing regimens, and formulations remains critical, as they can provide avenues for patentability beyond original claims.
FAQs
Q1: What specific molecular targets does U.S. Patent 10,137,127 cover?
Primarily monoclonal antibodies against α4 integrin, a key molecule involved in immune cell trafficking associated with conditions like MS.
Q2: Can this patent block biosimilar or generic versions of existing therapies like Natalizumab?
Potentially, if the biosimilar employs the same target and within the claimed use parameters; however, nuances in claims and legal validity may influence enforcement.
Q3: Does the patent encompass all autoimmune diseases?
No, the claims focus on a subset of autoimmune and inflammatory diseases, with specific emphasis on MS, RA, and Crohn’s disease.
Q4: What strategies exist for competitors to work around this patent?
Designing antibodies targeting different epitopes, using alternative immune pathways, or developing small-molecule alternatives can circumvent the patent.
Q5: How does this patent influence clinical development strategies?
It guides companies to innovate around the described methods, explore new indications, or optimize dosing regimens to avoid infringing claims.
References
- U.S. Patent No. 10,137,127. Equillium, Inc., "Methods of treating or preventing certain indications with a pharmaceutical composition," issued Nov 27, 2018.
- European Patent Office (EPO), Patent family documents related to monoclonal antibodies for autoimmune diseases.
- FDA Briefing Documents and Regulatory Pathways for biologic therapies targeting α4 integrins.
- Harrison, Jennifer, et al. “Patent landscape for biologics targeting immune cell trafficking in autoimmune diseases,” BioWorld, 2020.
- World Intellectual Property Organization (WIPO). International patent applications concerning anti-α4 integrin therapies, published 2016-2019.
Note: Always consult the full patent text and related legal advice for comprehensive due diligence.
More… ↓
⤷ Start Trial
|
